Navigation Links
Clarient Reports 2009 Third Quarter; Nine Month Results
Date:11/3/2009

--- --- ------ --- Net loss applicable to common stockholders $(3,235) $(2,214) $(7,652) $(7,427) ======= ======= ======= ======= Net income (loss) per share applicable to common stockholders- basic and diluted: Loss from continuing operations $(0.04) $(0.03) $(0.11) $(0.10) Income from discontinued operations - - 0.01 - --- --- ---- --- Net loss applicable to Common stockholders $(0.04) $(0.03) $(0.10) $(0.10) ====== ====== ====== ====== Weighted-average number of common shares outstanding - basic and diluted: 77,582,829 75,842,169 77,256,895 74,307,956


                                 Clarient, Inc.
          Reconciliation of Loss from Continuing Operations to "Adjusted
                                      EBITDA"

                                 Three months ended       Nine months ended
                                    September 30,            September 30,
                                  2009      2008(*)       2009        2008(*)
                                  ----       ------       ----        ------
    Loss from Continuing
     Operations, before income
     taxes                     $(3,235)    $(2,214)    $(4,862)      $(7,421)
    Income tax expense
     (benefit)                       -           -        (599)            6
    Interest Expense, net          144       2,399       4,056         5,747
    Depreciation &
     Amortization                1,039         961       2,820         2,815
    Stock Compensation Expense     501         241       1,640         1,424
                                  
'/>"/>
SOURCE Clarient, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Clarient to Present at Noble Financials 5th Annual Equity Conference on Tuesday, June 9th
2. Clarient Completes Second Tranche of Private Placement of Convertible Preferred Stock With Oak Investment Partners
3. Clarient Granted Exclusive License to Commercialize Breast Cancer Biomarker by Indiana University Research and Technology Corporation
4. Clarient Reports Strong Revenue Increase for Fourth Quarter and Full-Year 2008
5. [video] Ronald Andrews, CEO of Clarient, Inc. Discusses Agreement With University of Pennsylvania School of Medicine on WallSt.nets 3-Minute Press Show
6. Clarient Names Raymond J. Land Senior Vice President and Chief Financial Officer
7. Jim Agnello to Resign as Clarient Chief Financial Officer
8. Clarient Announces Fourth Quarter and Year-End 2007 Financial Results
9. CombiMatrix and Clarient Collaborate to Market, Sell Novel Genomics-Based Test for Chronic Lymphotic Leukemia (CLL)
10. Clarient to Commercialize Novel Breast Cancer Profile
11. Clarient CEO Ron Andrews to Participate in OneMedPlace Emerging Healthcare Technologies Finance Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Poway, CA (PRWEB) July 10, 2014 Robert ... Regenerative Veterinary Medicine company, is proud to announce the relaunch ... Pets, launching with a new series called “ What are ... to give an honest and straightforward foundation in the basics ... an educated decision on the right type of treatment when ...
(Date:7/10/2014)... Montreal, QC (PRWEB) July 10, 2014 ... comfort and convenience. This rejuvenating device now comes with a ... that develops over time. , The new cup is thinner ... This design works to target rough, thin and uneven surfaces ... original firm cup for a stimulating treatment on areas such ...
(Date:7/10/2014)... , July 10, 2014  Franciscan St. ... of capnography for respiratory monitoring outside the ... healthcare leaders in embracing state-of-the-art patient safety ... patients are breathing and can alert medical ... measuring the amount of carbon dioxide the ...
(Date:7/10/2014)... 2014  Kainos Capital, a firm specializing in acquiring ... it has acquired the Slim-Fast brand from Unilever. Unilever ... of the transaction were not disclosed. Slim-Fast ... that markets ready-to-drink shakes, powders, bars and snacks to ... and in the United Kingdom ...
Breaking Biology Technology:Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2Kainos Capital Acquires Slim-Fast From Unilever 2
... , , NATICK, Mass., ... BSX ) today announced that it has entered into ... held company offering advanced testing solutions for urinary incontinence. ... that combines staffing, equipment, supplies and results analysis, helping ...
... WEST CONSHOHOCKEN, Pa., Sept. 14 Cadient ... healthcare industry, today announced that it has been ranked on the ... companies in the country for the third consecutive year. Moving ... of this prestigious roster. The company experienced 124.3 percent growth ...
... , HOPKINTON, Mass., Sept. 14 ... leading provider of tools and services for drug discovery and ... vivo imaging system, the latest addition to the IVIS product ... fluorescence molecular optical imaging with the anatomical precision of digital ...
Cached Biology Technology:Boston Scientific's Urology/Gynecology Business Forms Marketing Alliance with Bladder Health Network 2Boston Scientific's Urology/Gynecology Business Forms Marketing Alliance with Bladder Health Network 3Cadient Group Ranks on Inc. 5000 List of Fastest-Growing Companies for Third Consecutive Year 2Caliper Life Sciences Launches IVIS(R) In Vivo Imaging System with X-Ray 2Caliper Life Sciences Launches IVIS(R) In Vivo Imaging System with X-Ray 3
(Date:7/11/2014)... increased risk of kidney injury related to the use ... mass of HES molecules, according to a report in ... International Anesthesia Research Society (IARS). , The "total mass ... on cultured human renal proximal tubule cells (PTCs), concludes ... of University Hospital Wrzburg, Austria. Other factorssuch as ...
(Date:7/11/2014)... that under the normal circumstances, astrocytes participate ... neuronal environment, and exhibit therapeutic and repairing ... Previous studies have found that nerve cells ... induction have reduced viability, which produces influences ... Yuan, Kailuan General Hospital, Hebei United University, ...
(Date:7/11/2014)... toxins to study the proteins that let nerve cells ... have stumbled upon a biological tactic that may offer ... in a safe and environmentally responsible way. , ... for one species and harmless for a closely related ... pests without harming beneficial species like bees. A summary ...
Breaking Biology News(10 mins):In lab studies, hydroxyethyl starch has direct harmful effects on kidney cells 2Potent spider toxin 'electrocutes' German, not American, cockroaches 2Potent spider toxin 'electrocutes' German, not American, cockroaches 3
... a novel H7N9 influenza virus was identified in China ... humans, resulting in some deaths. A group of scientists, ... Laboratory, State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary ... the origins of this novel H7N9 influenza virus (Shi ...
... University of Alberta researchers were certainly surprised when they ... vegetation that had previously been grazed on by caterpillars ... U of A biology researcher Isabel C. Barrio analyzed ... vegetation in alpine areas of the southwest Yukon. The ...
... with bacteria that shrug off existing antibiotics and sterilization ... of selective antimicrobial agents that do not rely on ... which can be custom-designed to recognize the shape of ... the Journal of the American Chemical Society . ...
Cached Biology News:Source identification of H7N9 influenza virus causing human infections 2Source identification of H7N9 influenza virus causing human infections 3Discovered: A mammal and bug food co-op in the High Arctic 2
Kit includes your choice of reagents for labeling 3 x 10 9 cells and EasySep magnet....
Plasmid expressing PLAP reporter gene....
Puromycin resistance gene (pac), provided in a pORF plasmid. pORF is an expression plasmid selectable with Ampicillin....
...
Biology Products: